TP53 and breast cancer: Thus, treatment with APR-246 may impair mut-p53-dependent NRF2 inhibition of xCT, increasing its expression (Figure 7, central panel), as shown by [25] using esophageal cancer cells and as confirmed here by our data on breast cancer.